{"product_id":"myriad-swot-analysis","title":"Myriad SWOT Analysis","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Myriad’s internal and external business factors\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a simple, high-level SWOT template for fast decision-making. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eMyriad SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThe analysis displayed here is the actual Myriad SWOT document. What you see now is what you get post-purchase.\u003c\/p\u003e\n\u003cp\u003eNo variations—this preview mirrors the complete report's format \u0026amp; depth.\u003c\/p\u003e\n\u003cp\u003eGet the whole document, in its entirety, right after checkout.\u003c\/p\u003e\n\u003cp\u003eIt’s the same professional, insightful, and fully realized analysis. \u003c\/p\u003e\n\u003cp\u003ePurchase to unlock the comprehensive version immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eSWOT Analysis Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis is just a taste of the comprehensive Myriad SWOT analysis. Explore key strengths, weaknesses, opportunities, and threats shaping the company's trajectory. We've touched on a few strategic points, but the full analysis delves deeper. Uncover crucial financial context and expert commentary.\u003c\/p\u003e\n\u003cp\u003eWant the complete picture? Purchase the full SWOT analysis for in-depth insights. Access a fully editable report for strategy, planning, and smarter investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading Position in Genetic Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics dominates the genetic testing market, especially in oncology and hereditary cancer screening. They hold a substantial market share due to their strategic focus. In 2024, Myriad's revenue reached $700 million, reflecting their strong market presence. Their investment in key areas secures their leading status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics' strengths include a strong intellectual property portfolio. This portfolio includes patents for oncology diagnostics, hereditary cancer screening, and molecular diagnostic technologies. These patents provide a competitive edge, with protection extending into 2035. For instance, in 2024, Myriad's IP portfolio supported its revenue from diagnostic tests, which reached $687 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Partnership Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics benefits from strong partnerships, including collaborations with over 2000 healthcare providers. These relationships facilitate broader market access and test adoption. In 2024, collaborations boosted test volume by 10% year-over-year. This network supports clinical integration and research advancements, vital for Myriad's growth. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Revenue Streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics benefits from diversified revenue streams. While known for hereditary cancer testing, they've expanded into pharmacogenomics and prenatal testing. This strategy reduces dependence on a single product line. In 2024, these new segments showed impressive growth, contributing to overall financial stability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePharmacogenomics revenue grew 18% in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePrenatal testing saw a 12% increase in the same year.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHereditary cancer testing still accounts for a significant portion, but diversification is key.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovation and Technology Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics is focusing on innovation through R\u0026amp;D, including new technologies such as molecular residual disease (MRD) assays and integrating AI. Their 'Labs of the Future' initiative aims to boost efficiency and lower costs. In Q1 2024, Myriad's R\u0026amp;D expenses were $33.6 million. This investment is crucial for staying competitive.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eQ1 2024 R\u0026amp;D expenses: $33.6 million\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on MRD assays and AI integration\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e'Labs of the Future' initiative for efficiency\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetic Testing Powerhouse: Market Leadership \u0026amp; Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad's dominance in genetic testing, especially oncology, highlights a core strength. A strong IP portfolio, offering a competitive edge, also protects its market position. Furthermore, diversified revenue streams and strategic innovation support continued growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Strength\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003e2024 Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Leader\u003c\/td\u003e\n\u003ctd\u003eFocus on oncology \u0026amp; hereditary cancer screening.\u003c\/td\u003e\n\u003ctd\u003e$700M Revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Portfolio\u003c\/td\u003e\n\u003ctd\u003ePatents on diagnostics \u0026amp; screening until 2035.\u003c\/td\u003e\n\u003ctd\u003e$687M from diagnostic tests\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiversified Revenue\u003c\/td\u003e\n\u003ctd\u003ePharmacogenomics, prenatal tests.\u003c\/td\u003e\n\u003ctd\u003ePGx up 18%, Prenatal +12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on a Limited Number of Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics' reliance on a limited product range, especially hereditary cancer testing, poses a weakness. In 2024, these tests still generated a significant portion of the company's $770 million revenue. This concentration exposes Myriad to risks from market changes or reimbursement policy adjustments. For instance, a decline in demand or coverage for a key test could severely impact financial performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Resources Required for Regulatory Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLaunching genetic tests demands significant resources for regulatory approvals and compliance. This includes substantial financial investments in submissions. The process is lengthy, potentially affecting operational efficiency. For example, the FDA approval for a new diagnostic test can cost between $1 million to $10 million, and take 1-3 years. This impacts cash flow. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChallenges in Market Penetration and Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad faces intense competition in the genetic diagnostics market. The company has seen its market share decrease in specific segments. Maintaining a competitive edge is difficult against rivals with innovative products. In 2024, Myriad's revenue was $696.5 million, reflecting these challenges.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReimbursement volatility poses a notable weakness. Changes in coverage policies from major payers, like UnitedHealthcare's 2024 decision to stop covering certain pharmacogenomic tests, directly affect revenue. Such shifts introduce uncertainty, potentially hindering financial forecasting and investment decisions. This volatility can lead to unpredictable revenue streams and reduced profitability. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eUnitedHealthcare's coverage changes in 2024 directly impacted diagnostic test providers.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThese changes can lead to revenue declines and increased financial risk.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eUncertainty in reimbursement complicates strategic planning.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeadership Transition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe planned leadership transition, with the current CEO's exit and a new CEO's arrival in mid-2025, poses execution risks, especially with key product launches. A smooth handover is critical to maintaining momentum and avoiding strategic disruptions. Any instability could impact investor confidence and market performance. The success of the new CEO will be vital. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eCEO turnover can lead to strategic shifts.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eExecution risk increases during product launches.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eInvestor confidence may be affected.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMarket performance could be volatile.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad's Vulnerabilities: Tests, Approvals, and Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad's revenue heavily depends on specific tests, creating vulnerability. Approvals demand considerable, time-consuming investment, affecting finances. Intense competition and reimbursement changes also hurt performance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Concentration\u003c\/td\u003e\n\u003ctd\u003eReliance on limited tests, especially hereditary cancer screening, remains high.\u003c\/td\u003e\n\u003ctd\u003eSusceptibility to market fluctuations and coverage shifts, exemplified by revenue figures in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Burden\u003c\/td\u003e\n\u003ctd\u003eLengthy, resource-intensive approval process.\u003c\/td\u003e\n\u003ctd\u003eIncreased operational costs and timelines affecting profitability; FDA approval can span years.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Pressures\u003c\/td\u003e\n\u003ctd\u003eFacing challenges in maintaining its market share amid increasing rivals.\u003c\/td\u003e\n\u003ctd\u003eImpact on market performance, with Myriad's reported revenues fluctuating.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement Volatility\u003c\/td\u003e\n\u003ctd\u003eChanging coverage from key payers; i.e., UnitedHealthcare.\u003c\/td\u003e\n\u003ctd\u003eUncertain revenue streams and potential profitability reduction.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56069053153664,"sku":"myriad-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/myriad-swot-analysis.png?v=1749378191","url":"https:\/\/swotanalysistemplates.com\/products\/myriad-swot-analysis","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}